By Marilyn Haddrill in allaboutvision.com August 20, 2018 Age-related macular degeneration also called macular degeneration, AMD or ARMD is deterioration of the macula, which is the small central area of the retina of the eye that controls visual ac

By Tetsuo Ashizawa et al. in Nature Reviews Neurology 2018 Abstract: The spinocerebellar ataxias (SCAs) comprise more than 40 autosomal dominant neurodegenerative disorders that present principally with progressive ataxia. Within the past few years,

By Santiago Perez et al. in Movement Disorders Clinical Practice February 2, 2015 Abstract: MSA is a progressive neurodegenerative disorder characterized by autonomic failure and a variable combination of poor levodopa‐responsive parkinsonism and cer

By Phillip A, Lo et al. in The Lancet. Neurology October 18, 2018 Abstract: No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system at

From CISION PR News, England July 8, 2015 A remarkable research initiative is emerging in the North-West of England through collaboration between the Association for the Independence of Disabled People (AID) and medical researchers at Lancaster Unive

From News-Medical.net May 17, 2018 An international study led by biochemists at the University of Liverpool has shown that the drug-molecule ebselen can correct many of the toxic characteristics of a protein that causes some cases of hereditary motor

From MND Scotland August 7, 2018 MND Scotland has announced the launch of the first Motor Neurone Disease (MND) clinical drug trial in Scotland, in over 20 years. MND Scotland, who is part-funding the study in Glasgow, is committing over 1.5 million

By Helen McArdle in HeraldScotland.com August, 7, 2017 PATIENTS in Scotland are being sought for the first clinical trial in 20 years into a potential new treatment for motor neurone disease that scientists hope will slow its progression. Researche

FDA News Release May 5, 2017 The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrigs disease. After learning about the use of edaravone

By Dr. Maria Simbra in CBS Pittsburgh August 11, 2017 Father, husband, and vacuum technology coordinator Rene Fogarty is the first person in the United States to get a new drug called Radicava. Its for ALS - amyotrophic lateral sclerosis - also know

From Hospital for Special Surgery,New York, October 25, 2018 Researchers from the Marcia Dunn and Jonathan Sobel Department of Neurology at Hospital for Special Surgery (HSS) in New York City have announced the opening of recruitment for a phase 3 in

Posted on July 1, 2015 EuroStemCell Over 400,000 people in the EU have multiple sclerosis (MS). It can cause blurred vision, extreme fatigue, pain, numbness, loss of movement and speech problems. It is the most common disease causing disability in y